Sanofi said it is pivoting its messenger RNA vaccine (mRNA) program—acquired over the summer when it bought Translate Bio for $3.2 billion—away from COVID-19 and toward influenza and other pathogens, despite announcing positive Phase I/II data for the vaccine candidate it had been co-developing with Translate.
Thomas Triomphe, executive vice president, Sanofi Pasteur, told reporters Tuesday that Sanofi was vacating the crowded COVID-19 vaccine field after concluding that its mRNA vaccine program stood a better chance of commercial success by refocusing its now clinically validated platform technology to the flu and other diseases.
